{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:12:51Z","timestamp":1757621571207,"version":"3.44.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-025-05308-w","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T17:20:30Z","timestamp":1754328030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A mutation in transthyretin gene in a Mexican patient leading to hereditary amyloidosis: a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Muhammad Reebal","family":"Malik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarun","family":"Dalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zubair","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"5308_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, Bisogni G, Sabatelli M. Diagnosis and treatment of hereditary transthyretin amyloidosis (hATTR) polyneuropathy: current perspectives on improving patient care. Ther Clin Risk Manag. 2020;16:109\u201323.","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"5308_CR2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/gim.2016.200","volume":"19","author":"JN Buxbaum","year":"2017","unstructured":"Buxbaum JN, Ruberg FL. Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genet Med. 2017;19(7):733\u201342.","journal-title":"Genet Med"},{"issue":"1","key":"5308_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/humu.1380040110","volume":"4","author":"A Ferlini","year":"1994","unstructured":"Ferlini A, Patrosso MC, Repetto M, Frattini A, Villa A, Fini S, et al. A new mutation (TTR Ala-47) in the transthyretin gene associated with hereditary amyloidosis. Hum Mutat. 1994;4(1):61\u20134.","journal-title":"Hum Mutat"},{"issue":"6","key":"5308_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ehf2.12518","volume":"6","author":"H Yamamoto","year":"2019","unstructured":"Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019;6(6):1128\u201339.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"5308_CR5","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7\u201322.","journal-title":"Circulation"},{"issue":"22","key":"5308_CR6","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/j.jacc.2007.08.028","volume":"50","author":"JB Selvanayagam","year":"2007","unstructured":"Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol. 2007;50(22):2101\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5308_CR7","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/diagnostics11060996","volume":"11","author":"W Li","year":"2021","unstructured":"Li W, Uppal D, Wang YC, Xu X, Kokkinidis DG, Travin MI, et al. Nuclear imaging for the diagnosis of cardiac amyloidosis in 2021. Diagnostics. 2021;11(6):996.","journal-title":"Diagnostics"},{"issue":"Suppl 2","key":"5308_CR8","doi-asserted-by":"publisher","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","volume":"18","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med. 2018;18(Suppl 2):s30\u20135.","journal-title":"Clin Med"},{"issue":"24","key":"5308_CR9","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312.","journal-title":"Circulation"},{"issue":"2","key":"5308_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/joim.12383","volume":"278","author":"KS Patel","year":"2015","unstructured":"Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015;278(2):126\u201344.","journal-title":"J Intern Med"},{"issue":"2","key":"5308_CR11","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ejhf.2027","volume":"23","author":"T Damy","year":"2021","unstructured":"Damy T, Garcia-Pavia P, Hanna M, Judge DP, Merlini G, Gundapaneni B, et al. Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23(2):277\u201385.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"5308_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"key":"5308_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10444-4","author":"AA Girard","year":"2024","unstructured":"Girard AA, Sperry BW. Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Fail Rev. 2024. https:\/\/doi.org\/10.1007\/s10741-024-10444-4.","journal-title":"Heart Fail Rev"},{"key":"5308_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suac121.654","author":"R Authors","year":"2022","unstructured":"Authors R, Garcia-pavia P, Gillmore J, Kale P, Berk J, Maurer M, et al. 77 Helios-A: 18-month exploratory cardiac results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis. Eur Heart J Suppl. 2022. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac121.654.","journal-title":"Eur Heart J Suppl"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05308-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05308-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05308-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:56:56Z","timestamp":1757339816000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-025-05308-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5308"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05308-w","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We obtained approval to present this case from the ethical board of University of Kansas Medical Center and obtained permission and informed consent from our patient to present his history and findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}